ADAM10 and neoplasm: To further link this regulatory mechanism to in vivo tumorigenesis in HNC-TICs, we subcutaneously transplanted parental CD44−ALDH1−, CD44−ALDH1−/Spg-Ctrl, CD44−ALDH1−/Spg-miR-494, CD44−ALDH1−/Spg-miR-494+sh-Luc., and CD44−ALDH1−/Spg-miR-494+sh-Bmi1+sh-ADAM10 cells in immunocompromised mice and monitored the tumor growth up to 6 weeks.